WO2022031948A1 - Procédés faisant appel à des lymphocytes t pour prédire l'immunogénicité d'un polypeptide - Google Patents

Procédés faisant appel à des lymphocytes t pour prédire l'immunogénicité d'un polypeptide Download PDF

Info

Publication number
WO2022031948A1
WO2022031948A1 PCT/US2021/044704 US2021044704W WO2022031948A1 WO 2022031948 A1 WO2022031948 A1 WO 2022031948A1 US 2021044704 W US2021044704 W US 2021044704W WO 2022031948 A1 WO2022031948 A1 WO 2022031948A1
Authority
WO
WIPO (PCT)
Prior art keywords
lymphocytes
donors
index value
composition
stimulation index
Prior art date
Application number
PCT/US2021/044704
Other languages
English (en)
Inventor
Shan Chung
Sivan COHEN
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Priority to EP21769836.4A priority Critical patent/EP4192942A1/fr
Priority to CN202180049073.8A priority patent/CN115836122A/zh
Priority to JP2023504732A priority patent/JP2023537683A/ja
Publication of WO2022031948A1 publication Critical patent/WO2022031948A1/fr
Priority to US18/104,825 priority patent/US20230184747A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins

Definitions

  • the present disclosure relates to methods for determining the propensity of a composition to elicit production of anti-drug antibodies (AD As) and kits for performing such methods.
  • Therapeutics have greatly improved the treatment of an increasing number of serious and difficult to treat diseases.
  • such therapeutics may elicit the production of anti-drug antibodies (AD As) when administered to a patient.
  • AD As can have neutralizing effects on the therapeutic. These neutralizing effects can include limiting the activity of the therapeutic, increasing clearance of the therapeutic, and a potential reduction in overall clinical response attributable to administration of the therapeutic.
  • the production of ADAs has also coincided with the occurrence of severe adverse events in patients, including hypersensitivity reactions and anaphylaxis.
  • MHC major histocompatibility complex
  • MAPPs Il-associated peptide proteomics
  • the peptides are loaded onto MHC class II molecules and presented on the surface of the APC. Immunoprecipitating and analyzing these MHC-peptide complexes via liquid chromatography mass spectrometry (LC/MS) allows for identification of potentially immunogenic epitopes in the therapeutic.
  • Another technique for determining the immunogenic potential of a preclinical therapeutic candidate is the T cell proliferation assay, which involves the detection of T cell proliferation after co-culture with APCs, e.g., dendritic cells, that have been incubated with the polypeptide-based therapeutic of interest.
  • T cell proliferation assay which involves the detection of T cell proliferation after co-culture with APCs, e.g., dendritic cells, that have been incubated with the polypeptide-based therapeutic of interest.
  • a method of the present disclosure can include (a) culturing lymphocytes in the presence of the composition to generate stimulated lymphocytes; (b) culturing lymphocytes in the absence of the composition to generate unstimulated lymphocytes; (c) determining the percentage of the stimulated lymphocytes that are CD4+ and express: (i) CD134; (ii) CD137; or (iii) CD134 and CD 137; (d) determining the percentage of the unstimulated lymphocytes that are CD4+ and express: (i) CD134; (ii) CD137; or (iii) CD134 and CD137; and (e) calculating a stimulation index value.
  • the composition when the stimulation index value in (e) is greater than or equal to a reference stimulation index value then the composition has a greater propensity to elicit antibodies specific to said composition. In certain embodiments, when the stimulation index value in (e) is less than the reference stimulation index value then the composition has a lesser propensity to elicit antibodies specific to said composition.
  • the stimulation index value can be determined by: (i) dividing the percentage of stimulated lymphocytes determined in (c) with the percentage of unstimulated lymphocytes determined in (d), (ii) outlier sum analysis and/or (iii) linear regression. In certain embodiments, the lymphocytes are obtained from a single donor.
  • the lymphocytes are obtained from about 20 donors to about 50 donors, e.g., from about 35 to about 45 donors. In certain embodiments, the lymphocytes are obtained from at least about 20 donors, at least about 25 donors, at least about 30 donors, at least about 35 donors, at least about 40 donors or at least about 45 donors.
  • a method for determining the propensity of a composition to elicit the production of antibodies specific to the composition includes (a) separately culturing lymphocytes from individual donors in the presence of the composition to generate stimulated lymphocytes; (b) separately culturing lymphocytes from the individual donors in the absence of the composition to generate unstimulated lymphocytes; (c) determining the percentage of the stimulated lymphocytes from the individual donors that are CD4+ and express: (i) CD134; (ii) CD137; or (iii) CD134 and CD137; (d) determining the percentage of the unstimulated lymphocytes from the donors that are CD4+ and express: (i) CD134; (ii) CD137; or (iii) CD134 and CD137; (e) calculating a stimulation index value for each of the donors; and (f) calculating a number of reactive lymphocyte donors where the donors’ stimulation index value is greater than or equal to a reference value stimulation index value and the number of unstimulated lymphocyte donors
  • the stimulation index value can be determined by: (i) dividing the percentage of stimulated lymphocytes of an individual donor determined in (c) with the percentage of unstimulated lymphocytes of that individual donor determined in (d), (ii) outlier sum analysis and/or (iii) linear regression.
  • the composition has a high propensity to elicit the production of antibodies specific to the composition if the number of stimulated donors is greater than 30% of the total number of donors. In certain embodiments, the composition has a low propensity to elicit the production of antibodies specific to the composition if the number of stimulated donors is less than 20% of the total number of donors.
  • the lymphocytes are obtained from about 20 donors to about 50 donors, e.g., from about 35 to about 45 donors. In certain embodiments, the lymphocytes are obtained from at least about 20 donors, at least about 25 donors, at least about 30 donors, at least about 35 donors, at least about 40 donors or at least about 45 donors.
  • the composition comprises a neoantigen.
  • the composition is a peptide, a polypeptide or a small molecule compound.
  • the polypeptide is an antibody or fragment thereof, e.g., the antibody or fragment thereof is a human, humanized or chimeric antibody.
  • the composition is an antibody-drug conjugate (ADC).
  • ADC antibody-drug conjugate
  • the antibody or fragment thereof is a bispecific antibody.
  • the method can include (a) culturing lymphocytes in the presence of the neoantigen to generate stimulated lymphocytes; (b) culturing lymphocytes in the absence of the neoantigen to generate unstimulated lymphocytes; (c) determining the percentage of the stimulated lymphocytes that are CD4+ and express: (i) CD134; (ii) CD137; or (iii) CD134 and CD137; (d) determining the percentage of the unstimulated lymphocytes that are CD4+ and express: (i) CD134; (ii) CD137; or (iii) CD134 and CD137; and (e) calculating a stimulation index value.
  • the stimulation index value can be determined by (i) dividing the percentage of stimulated lymphocytes determined in (c) with the percentage of unstimulated lymphocytes determined in (d), (ii) outlier sum analysis and/or (iii) by linear regression.
  • the stimulation index value in (e) is greater than or equal to a reference stimulation index value then the neoantigen has a greater propensity to elicit an immune response specific to the neoantigen and when the stimulation index value in (e) is less than the reference stimulation index value then the neoantigen has a lesser propensity to elicit an immune response specific to the neoantigen.
  • the reference stimulation index value is the stimulation index value of a reference composition, e.g., a composition that does not elicit production of AD As in a clinical setting or has a low propensity to elicit production of ADAs in a clinical setting.
  • the reference stimulation index value is from about 1.0 to about 4.0, z.e., from about 1.0 to about 2.0.
  • the reference stimulation index value is about 1.6 or greater, about 1.7 or greater or about 1.8 or greater.
  • the lymphocytes comprise T cells. In certain embodiments, at least 30% of the lymphocytes comprise T cells. In certain embodiments, the T cells are CD8-. In certain embodiments, at least 10% of the T cells comprise CD8- T cells. In certain embodiments, about IxlO 5 to about IxlO 7 lymphocytes are cultured with the composition. In certain embodiments, the lymphocytes are cultured with about 10 pg/ul to about 1,000 pg/ml of the composition. In certain embodiments, the lymphocytes are cultured with the composition for about 48 hours or less.
  • determining the percentage of the stimulated or the unstimulated lymphocytes that are CD4+ and express: (i) CD134; (ii) CD137; or (iii) CD134 and CD137 is performed by flow cytometry.
  • the present disclosure provides a method for determining the propensity of a composition to elicit the production of antibodies specific to said composition relative to a reference propensity.
  • the method can include (a) culturing antigen presenting cells (APCs) in the presence of the composition to generate stimulated APCs; (b) culturing APCs in the absence of the composition to generate unstimulated APCs; (c) separately culturing the stimulated APCs with CD4+ lymphocytes and the unstimulated APCs with CD4+ lymphocytes; (d) determining the percentage of the CD4+ lymphocytes cultured with the stimulated APCs that express: (i) CD134; (ii) CD137; or (iii) CD 134 and CD 137; (e) determining the percentage of the CD4+ lymphocytes cultured with the unstimulated APCs that express: (i) CD134; (ii) CD137; or (iii) CD134 and CD 137; and (f) calculating a stimulation index value.
  • APCs antigen presenting cells
  • the composition when the stimulation index value in (f) is greater than or equal to a reference stimulation index value then the composition has a greater propensity to elicit antibodies specific to said composition and when the stimulation index value in (f) is less than the reference stimulation index value then the composition has a lesser propensity to elicit antibodies specific to said composition.
  • the stimulation index value is determined by dividing the percentage of CD4+ lymphocytes determined in (d) with the percentage of CD4+ lymphocytes determined in (e). In certain embodiments, the stimulation index value is determined by outlier sum analysis or determined by linear regression.
  • the APCs are obtained from a single donor. In certain embodiments, the APCs are obtained from about 20 donors to about 50 donors.
  • the APCs are obtained from about 35 to about 45 donors. In certain embodiments, the APCs are obtained from at least about 20 donors, at least about 25 donors, at least about 30 donors, at least about 35 donors, at least about 40 donors or at least about 45 donors.
  • the present disclosure further provides a method for determining the propensity of a composition to elicit the production of antibodies specific to the composition, wherein the method comprises: (a) separately culturing APCs from individual donors in the presence of the composition to generate stimulated APCs; (b) separately culturing APCs from the individual donors in the absence of the composition to generate unstimulated APCs; (c) separately culturing the stimulated APCs with CD4+ lymphocytes and the unstimulated APCs with CD4+ lymphocytes; (d) determining the percentage of the CD4+ lymphocytes cultured with the stimulated APCs that express: (i) CD134; (ii) CD137; or (iii) CD134 and CD137; (e) determining the percentage of the CD4+ lymphocytes cultured with the unstimulated APCs that express: (i) CD 134; (ii) CD137; or (iii) CD134 and CD137; (f) calculating a stimulation index value for each
  • the composition has a high propensity to elicit the production of antibodies specific to the composition if the number of reactive donors is greater than 30% of the total number of donors and the composition has a low propensity to elicit the production of antibodies specific to the composition if the number of reactive donors is less than 20% of the total number of donors.
  • the stimulation index value is determined by dividing the percentage of CD4+ lymphocytes of an individual donor determined in (d) with the percentage of CD4+ lymphocytes of that individual donor determined in (e). In certain embodiments, the stimulation index value is determined by outlier sum analysis or determined by linear regression.
  • the stimulation index value is determined by dividing the percentage of CD4+ lymphocytes of an individual donor determined in (d) with the percentage of CD4+ lymphocytes of that individual donor determined in (e).
  • the APCs are obtained from about 20 donors to about 50 donors. In certain embodiments, the APCs are obtained from about 35 to about 45 donors. In certain embodiments, the APCs are obtained from at least about 20 donors, at least about 25 donors, at least about 30 donors, at least about 35 donors, at least about 40 donors or at least about 45 donors.
  • the present disclosure provides a method for determining the propensity of a neoantigen to elicit an immune response specific to said neoantigen relative to a reference antigen.
  • the method includes (a) culturing APCs in the presence of the neoantigen to generate stimulated APCs; (b) culturing APCs in the absence of the neoantigen to generate unstimulated APCs; (c) separately culturing the stimulated APCs with CD4+ lymphocytes and the unstimulated APCs with CD4+ lymphocytes; (d) determining the percentage of the CD4+ lymphocytes cultured with the stimulated APCs that express: (i) CD134; (ii) CD137; or (iii) CD134 and CD137; (e) determining the percentage of the CD4+ lymphocytes cultured with the unstimulated APCs that express: (i) CD134; (ii) CD137; or (iii) CD134 and CD
  • the neoantigen when the stimulation index value in (f) is greater than or equal to a reference stimulation index value then the neoantigen has a greater propensity to elicit an immune response specific to said neoantigen and when the stimulation index value in (f) is less than the reference stimulation index value then the neoantigen has a lesser propensity to elicit an immune response specific to said neoantigen.
  • the neoantigen is present in a complex with an MHC class II molecule.
  • the stimulation index value is determined by dividing the percentage of CD4+ lymphocytes determined in (d) with the percentage of CD4+ lymphocytes determined in (e).
  • the stimulation index value is determined by outlier sum analysis or determined by linear regression.
  • the APCs are obtained from about 20 donors to about 50 donors. In certain embodiments, the APCs are obtained from about 35 to about 45 donors. In certain embodiments, the APCs are obtained from at least about 20 donors, at least about 25 donors, at least about 30 donors, at least about 35 donors, at least about 40 donors or at least about 45 donors.
  • the reference stimulation index value is from about 1.0 to about 4.0, from about 1.0 to about 3.0 or from about 1.8 to about 3.0. In certain embodiments, the reference stimulation index value is about 1.6 or greater, about 1.7 or greater, about 1.8 or greater, about 1.9 or greater, about 2.0 or greater, about 2.1 or greater, about 2.2 or greater, about 2.3 or greater, about 2.4 or greater, about 2.5 or greater, about 2.6 or greater, about 2.7 or greater, about 2.8 or greater, about 2.9 or greater or about 3.0 or greater.
  • the CD4+ lymphocytes comprise CD8- T cells. In certain embodiments, at least 10% of the CD4+ lymphocytes are CD8- T cells.
  • the composition comprises a peptide, a polypeptide or a small molecule compound.
  • the peptide or polypeptide comprises a neoantigen.
  • the polypeptide is an antibody or fragment thereof.
  • the antibody is a human, humanized or chimeric antibody.
  • the composition is an antibody-drug conjugate (ADC).
  • about IxlO 5 to about IxlO 7 APCs are cultured with the composition and/or neoantigen.
  • the APCs are cultured with about 10 pg/ul to about 1,000 pg/ml of the composition and/or neoantigen.
  • the APCs are cultured with the composition and/or neoantigen for about 48 hours or less.
  • determining the percentage of the CD4+ lymphocytes that express: (i) CD134; (ii) CD137; or (iii) CD134 and CD137 is performed by flow cytometry.
  • the present disclosure further provides kits for performing any one of the methods of disclosed herein.
  • FIG. 1 displays a schematic of a non-limiting embodiment of a method for determining the propensity of a composition to elicit production of AD As.
  • FIG. 2 displays the FACS analysis of two different antibodies, AVASTIN® and bococizumab.
  • FIG. 3 displays the analysis of six (6) antibodies, AVASTIN®, GNE-aPCSK9 (also referred to as RG7652), alirocumab (PRALUENT®), evolocumab (REPATHA®), bococizumab and HA33, with different clinical ADA rates.
  • FIG. 4 A displays the number of donors that expressed CD 134 for AVASTIN®, HA33 and KLH.
  • FIG. 4B displays the number of donors that expressed CD137 for AVASTIN®, HA33 and KLH.
  • FIG. 4C displays the number of donors that expressed CD134 and CD137 for AVASTIN®, HA33 and KLH.
  • FIG. 4D displays the number of donors that expressed CD134 and/or CD137 for AVASTIN®, HA33 and KLH.
  • FIG. 5 displays that there is a correlation between the predicted immunogenicity as determined by the presently disclosed assay and the observed immunogenicity in the clinic.
  • FIG. 6A displays a schematic showing the antibody blocking of HLA-DR and HLA-II.
  • FIG. 6B displays the number of positive donors upon blocking of HLA-DR and HLA-II.
  • FIG. 7 displays that there is no correlation between IL-2 secretion in vitro and clinical immunogenicity.
  • FIG. 8 displays that there is no correlation between cytokine secretion in vitro and clinical immunogenicity.
  • FIG. 9 displays a schematic of a non-limiting embodiment of methods of the present disclosure for determining the propensity of a composition to elicit production of ADAs where isolated APCs are initially cultured with the composition and then those APCs are subsequently co-cultured with T cells and activation of the T cells is used to determine the propensity of the composition to elicit production of ADAs.
  • FIG. 10 displays a schematic of a non-limiting rapid embodiment of the methods of the present disclosure for determining the propensity of a composition to elicit production of ADAs where the APCs are initially cultured with the composition and then subsequently co-cultured with T cells and activation of the T cells is used to determine the propensity of the composition to elicit production of ADAs.
  • FIG. 11A displays the analysis of four (4) bispecific antibodies that have an antigen-binding domain that is specific for T cells.
  • the stimulation index (SI) value line indicates values greater than 1.8.
  • FIG. 1 IB displays the analysis of four (4) bispecific antibodies that have an antigen-binding domain that is specific for T cells.
  • the SI value line indicates values greater than 3.
  • FIG. 12A displays the analysis of two (2) bispecific antibodies that have an antigen-binding domain that is specific for T cells.
  • the SI value line indicates values greater than 1.8.
  • FIG. 12B displays the analysis of two (2) bispecific antibodies that have an antigen-binding domain that is specific for T cells.
  • the SI value line indicates values greater than 3.
  • FIG. 13 A displays a schematic of the T cell-activation assay that includes HLA blockage to show that the proposed immunogenicity is due to the therapeutic-specific activation of T cells.
  • FIG. 13B displays the analysis of the bispecific antibody TDB2 using the assay depicted in Fig. 13A.
  • FIG. 14 displays the analysis of a bispecific antibody produced by expression of its two antigen-binding domains in a single cell (TDB4A) or produced by a two cell system, where each cell expresses one of the two antigen-binding domains of the bispecific antibody (TDB4B).
  • compositions III. Compositions
  • antibody herein is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired antigen-binding activity.
  • antibody fragment refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds.
  • antibody fragments include but are not limited to Fv, Fab, Fab’, Fab’- SH, F(ab’)2; diabodies; linear antibodies; single-chain antibody molecules (e.g., scFv); and multispecific antibodies formed from antibody fragments.
  • an antibody “which binds” an antigen of interest is one that binds the antigen with sufficient affinity such that the antibody is useful as an assay reagent, e.g., as a detection antibody. Typically, such an antibody does not significantly cross-react with other polypeptides.
  • the term “specific binding” or “specifically binds to” or is “specific for” a particular polypeptide or an epitope on a particular polypeptide target means binding that is measurably different from a non-specific interaction. Specific binding can be measured, for example, by determining binding of a target molecule compared to binding of a control molecule, which generally is a molecule of similar structure that does not have binding activity.
  • Binding affinity refers to the strength of the sum total of noncovalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen).
  • binding affinity refers to intrinsic binding affinity which reflects a 1 : 1 interaction between members of a binding pair (e.g., antibody and antigen).
  • the affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (Ka). Affinity can be measured by common methods known in the art, including those described herein. Specific illustrative and exemplary embodiments for measuring binding affinity are described in the following.
  • chimeric antibody refers to an antibody in which a portion of the heavy and/or light chain is derived from a particular source or species, while the remainder of the heavy and/or light chain is derived from a different source or species.
  • the “class” of an antibody refers to the type of constant domain or constant region possessed by its heavy chain.
  • the heavy chain constant domains that correspond to the different classes of immunoglobulins are called a, 5, 8, y, and p, respectively.
  • cytotoxic agent refers to a substance that inhibits or prevents a cellular function and/or causes cell death or destruction.
  • Cytotoxic agents include, but are not limited to, radioactive isotopes (e.g., At 211 , 1 131 , 1 125 , Y 90 , Re 186 , Re 188 , and radioactive isotopes of Lu); chemotherapeutic agents or drugs (e.g., methotrexate, adriamicin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin or other intercalating agents); growth inhibitory agents; enzymes and fragments thereof such as nucleolytic enzymes; antibiotics; toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof; and the various
  • a “detection antibody,” as used herein, refers to an antibody that specifically binds a target molecule in a sample. Under certain conditions, the detection antibody forms a complex with the target molecule.
  • a detection antibody is capable of being detected either directly through a label, which may be detected, or indirectly, e.g., through use of another antibody that is labeled and that binds the detection antibody.
  • the detection antibody is typically conjugated to a moiety that is detectable by some means, for example, including but not limited to, fluorophore.
  • detecting is used herein, to include both qualitative and quantitative measurements of a target molecule or processed forms thereof. In certain embodiments, detecting includes identifying the mere presence of the target molecule as well as determining whether the target molecule is present at detectable levels.
  • “Effector functions” refer to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include: Clq binding and complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g., B cell receptor); and B cell activation.
  • Fc region herein is used to define a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region.
  • the term includes native sequence Fc regions and variant Fc regions.
  • a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl- terminus of the heavy chain.
  • the C-terminal lysine (Lys447) of the Fc region may or may not be present.
  • numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991.
  • “Framework” or “FR” refers to variable domain residues other than hypervariable region (CDR) residues.
  • the FR of a variable domain generally consists of four FR domains: FR1, FR2, FR3, and FR4. Accordingly, the CDR and FR sequences generally appear in the following sequence in VH (or VL): FR1-H1(L1)-FR2-H2(L2)- FR3-H3(L3)-FR4.
  • full-length antibody “intact antibody” and “whole antibody” are used herein interchangeably to refer to an antibody having a structure substantially similar to a native antibody structure or having heavy chains that contain an Fc region as defined herein.
  • a “human antibody” is one which possesses an amino acid sequence which corresponds to that of an antibody produced by a human or a human cell or derived from a non-human source that utilizes human antibody repertoires or other human antibodyencoding sequences. This definition of a human antibody specifically excludes a humanized antibody comprising non-human antigen-binding residues.
  • a “human consensus framework” is a framework which represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences.
  • the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences.
  • the subgroup of sequences is a subgroup as in Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 91-3242, Bethesda MD (1991), Vols. 1-3.
  • the subgroup is subgroup kappa I as in Kabat et al., supra.
  • the subgroup is subgroup III as in Kabat et al., supra.
  • a “humanized” antibody refers to a chimeric antibody comprising amino acid residues from non-human CDRs and amino acid residues from human FRs.
  • a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDRs (e.g., CDRs) correspond to those of a non-human antibody, and all or substantially all of the FRs correspond to those of a human antibody.
  • a humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody.
  • a “humanized form” of an antibody, e.g., a non-human antibody refers to an antibody that has undergone humanization.
  • hypervariable region refers to each of the regions of an antibody variable domain which are hypervariable in sequence (also referred to herein as “complementarity determining regions” or “CDRs”) and/or form structurally defined loops (“hypervariable loops”) and/or contain the antigen-contacting residues (“antigen contacts”).
  • CDR residues and other residues in the variable domain are numbered herein according to Kabat et al., supra.
  • antibodies comprise six CDRs: three in the VH (Hl, H2, H3), and three in the VL (LI, L2, L3).
  • Exemplary CDRs herein include:
  • an “immunoconjugate” refers to an antibody conjugated to one or more heterologous molecule(s), including but not limited to a cytotoxic agent.
  • an “individual,” “subject” or “donor” herein is a vertebrate, such as a human or non-human animal, for example, a mammal. Mammals include, but are not limited to, humans, non-human primates, farm animals, sport animals, rodents and pets. Non-limiting examples of non-human animal subjects include rodents such as mice, rats, hamsters, and guinea pigs; rabbits; dogs; cats; sheep; pigs; goats; cattle; horses; and non-human primates such as apes and monkeys. In certain embodiments, the individual, subject or donor is a human.
  • the term “in vitro’’’ refers to an artificial environment and to processes or reactions that occur within an artificial environment. In vitro environments exemplified, but are not limited to, test tubes and cell cultures.
  • the term “in vivo” refers to the natural environment (e.g., an animal or a cell) and to processes or reactions that occur within a natural environment, such as embryonic development, cell differentiation, neural tube formation, etc.
  • an “isolated” antibody is one which has been separated from a component of its natural environment.
  • an antibody is purified to greater than 95% or 99% purity as determined by, for example, electrophoretic (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatographic (e.g., ion exchange or reverse phase HPLC).
  • electrophoretic e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis
  • chromatographic e.g., ion exchange or reverse phase HPLC
  • label refers to any chemical group or moiety that can be linked to a substance that is to be detected or quantitated, e.g., an antibody.
  • a label is a detectable label that is suitable for the sensitive detection or quantification of a substance.
  • detectable labels include, but are not limited to, luminescent labels, e.g., fluorescent, phosphorescent, chemiluminescent, bioluminescent and electrochemiluminescent labels, radioactive labels, enzymes, particles, magnetic substances, electroactive species and the like.
  • a detectable label can signal its presence by participating in specific binding reactions.
  • Nonlimiting examples of such labels include haptens, antibodies, biotin, streptavidin, his-tag, nitrilotriacetic acid, glutathione S -transferase, glutathione and the like.
  • the term “monoclonal antibody,” as used herein, refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and/or bind the same epitope, except for possible variant antibodies, e.g., containing naturally occurring mutations or arising during production of a monoclonal antibody preparation, such variants generally being present in minor amounts.
  • polyclonal antibody preparations typically include different antibodies directed against different determinants (epitopes)
  • each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen.
  • the modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.
  • the monoclonal antibodies to be used in accordance with the presently disclosed subject matter may be made by a variety of techniques, including but not limited to the hybridoma method, recombinant DNA methods, phage-display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, such methods and other exemplary methods for making monoclonal antibodies being described herein.
  • “Native antibodies” refer to naturally occurring immunoglobulin molecules with varying structures.
  • native IgG antibodies are heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light chains and two identical heavy chains that are disulfide-bonded. From N- to C-terminus, each heavy chain has a variable region (VH), also called a variable heavy domain or a heavy chain variable domain, followed by three constant domains (CHI, CH2, and CH3). Similarly, from N- to C-terminus, each light chain has a variable region (VL), also called a variable light domain or a light chain variable domain, followed by a constant light (CL) domain.
  • VH variable heavy domain
  • VL variable region
  • the light chain of an antibody may be assigned to one of two types, called kappa (K) and lambda (X), based on the amino acid sequence of its constant domain.
  • nucleic acid molecule or “polynucleotide” includes any compound and/or substance that comprises a polymer of nucleotides.
  • Each nucleotide is composed of a base, specifically a purine- or pyrimidine base (i.e., cytosine (C), guanine (G), adenine (A), thymine (T) or uracil (U)), a sugar (i. e. , deoxyribose or ribose), and a phosphate group.
  • cytosine (C), guanine (G), adenine (A), thymine (T) or uracil (U) a sugar (i. e. , deoxyribose or ribose), and a phosphate group.
  • C cytosine
  • G guanine
  • A adenine
  • T thymine
  • U uracil
  • sugar i. e.
  • nucleic acid molecule encompasses deoxyribonucleic acid (DNA) including, e.g., complementary DNA (cDNA) and genomic DNA, ribonucleic acid (RNA), in particular messenger RNA (mRNA), synthetic forms of DNA or RNA, and mixed polymers comprising two or more of these molecules.
  • DNA deoxyribonucleic acid
  • RNA ribonucleic acid
  • mRNA messenger RNA
  • the nucleic acid molecule can be linear or circular.
  • nucleic acid molecule includes both, sense and antisense strands, as well as single stranded and double stranded forms.
  • the herein described nucleic acid molecule can contain naturally occurring or non-naturally occurring nucleotides.
  • nucleic acid molecules also encompass DNA and RNA molecules which are suitable as a vector for direct expression of an antibody of the present disclosure in vitro and/or in vivo, e.g., in a host or patient.
  • DNA e.g., cDNA
  • RNA e.g., mRNA
  • mRNA can be chemically modified to enhance the stability of the RNA vector and/or expression of the encoded molecule so that mRNA can be injected into a subject to generate the antibody in vivo (see, e.g., Stadler et al., Nature Medicine 2017, published online 12 June 2017, doi: 10.1038/nm.4356 or EP 2 101 823 Bl).
  • “Purified” polypeptide refers to a polypeptide that has been increased in purity, such that it exists in a form that is more pure than it exists in its natural environment and/or when initially synthesized and/or amplified under laboratory conditions. Purity is a relative term and does not necessarily mean absolute purity.
  • package insert refers to instructions customarily included in commercial packages that contain information concerning the use of the components of the package.
  • Percent (%) amino acid sequence identity with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
  • % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2.
  • the ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087.
  • the ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, California, or may be compiled from the source code.
  • the ALIGN-2 program should be compiled for use on a UNIX operating system, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.
  • % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B is calculated as follows:
  • polypeptide and “protein,” as used interchangeably herein, refer to polymers of amino acids of any length.
  • the polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids.
  • the terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation or any other manipulation or modification, such as conjugation with a labeling component.
  • polypeptides containing one or more analogs of an amino acid including, for example, unnatural amino acids, etc.
  • the terms “polypeptide” and “protein” as used herein specifically encompass antibodies.
  • recombinant protein refers generally to peptides and proteins that have been genetically manipulated. In certain embodiments, such recombinant proteins are “heterologous,” /. ⁇ ., foreign to the cell being utilized.
  • sample refers to a small portion of a larger quantity of material.
  • a sample includes, but is not limited to, cells in culture, cell supernatants, cell lysates, serum, blood plasma, biological fluid (e.g., blood, plasma, serum, stool, urine, lymphatic fluid, ascites, ductal lavage, saliva and cerebrospinal fluid) and tissue samples.
  • biological fluid e.g., blood, plasma, serum, stool, urine, lymphatic fluid, ascites, ductal lavage, saliva and cerebrospinal fluid
  • the source of the sample may be solid tissue (e.g., from a fresh, frozen, and/or preserved organ, tissue sample, biopsy or aspirate), blood or any blood constituents, bodily fluids (such as, e.g., urine, lymph, cerebral spinal fluid, amniotic fluid, peritoneal fluid or interstitial fluid), or cells from the individual, including circulating cells.
  • tissue e.g., from a fresh, frozen, and/or preserved organ, tissue sample, biopsy or aspirate
  • bodily fluids such as, e.g., urine, lymph, cerebral spinal fluid, amniotic fluid, peritoneal fluid or interstitial fluid
  • cells from the individual including circulating cells.
  • the term “variable region” or “variable domain” refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to antigen.
  • the variable domains of the heavy chain and light chain (VH and VL, respectively) of a native antibody generally have similar structures, with each domain comprising four conserved framework regions
  • VH or VL domain may be sufficient to confer antigen-binding specificity.
  • antibodies that bind a particular antigen may be isolated using a VH or VL domain from an antibody that binds the antigen to screen a library of complementary VL or VH domains, respectively. See, e.g., Portolano et al., J. Immunol. 150:880-887 (1993); Clarkson et al., Nature 352:624-628 (1991).
  • the presently disclosed subject matter provides methods for determining the propensity of a composition that comprises a therapeutic, e.g., a polypeptide or a fragment thereof, to elicit production of anti-drug antibodies (AD As).
  • a therapeutic e.g., a polypeptide or a fragment thereof
  • the presently disclosed methods can be used to determine the propensity of a composition comprising an antibody or fragment thereof or an antibody-drug conjugate (ADC) to elicit production of AD As.
  • ADC antibody-drug conjugate
  • kits for performing the methods disclosed herein are also provided herein.
  • the methods of the present disclosure can be used to identify polypeptide variants, e.g., antibody variants, that have a reduced propensity to elicit production of AD As compared to the parent polypeptide, e.g., a parent antibody.
  • the methods disclosed herein can be used to analyze newly- developed polypeptides, e.g., antibodies.
  • the methods disclosed herein can be used to identify a polypeptide, e.g., an antibody, that has a lower propensity to elicit ADA from a larger repertoire of polypeptides that specifically bind to the same antigen.
  • methods of the present disclosure can be used to determine the immunogenic potential of a newly developed polypeptide, e.g., antibody, prior to clinical studies.
  • the present disclosed methods can be used to determine the immunogenicity potential of aggregates of a polypeptide, e.g., antibody.
  • the presently disclosed methods can be used to analyze the immunogenicity of sequence variants of an antibody, e.g., those that arise during the manufacture and/or production of the antibody.
  • the presently disclosed methods can be used to analyze the immunogenicity of a neoantigen.
  • the presently disclosed methods can be used to analyze the immunogenicity of a peptide.
  • methods of the present disclosure can include culturing lymphocytes in the presence of the composition to generate stimulated lymphocytes.
  • the method can further include culturing lymphocytes in the absence of the composition to generate unstimulated lymphocytes.
  • the lymphocytes can be cultured in the presence of the composition, e.g., for about 24 to about 72 hours.
  • the lymphocytes can be cultured in the presence of the polypeptide from about 12 to about 72 hours, about 12 to about 60 hours, about 12 hours to about 48 hours, about 12 hours to about 24 hours, about 24 hours to about 72 hours, about 24 hours to about 60 hours, about 24 to about 48 hours, about 48 hours to about 72 hours or about 48 hours to about 60 hours.
  • the lymphocytes can be cultured in the presence of the composition for about 48 hours or less.
  • lymphocytes used in the presently disclosed methods can depend on the size of the culture dishes and/or plates used.
  • lymphocytes can be used at a concentration from about IxlO 5 to about IxlO 7 cells/ml, e.g., about 2xl0 6 cells/ml, e.g., in a 24-well plate and/or 96-well plate.
  • the number of lymphocytes used can be from about IxlO 5 to about 9xl0 6 cells, from about 3xl0 5 to about 8xl0 6 cells, from about 3xl0 5 to about 7xl0 6 cells, from about 4xl0 5 to about 6xl0 6 cells, from about 5xl0 5 to about 5xl0 6 cells, from about 6xl0 5 to about 4xl0 6 cells, from about 7xl0 5 to about 3xl0 6 cells, from about 8xl0 5 to about 2xl0 6 cells, from about 9xl0 5 to about 2xl0 6 cells or from about 9xl0 5 to about IxlO 6 cells. In certain embodiments, about IxlO 6 cells lymphocytes are used.
  • the number of lymphocytes used can be from about IxlO 5 cells to about 3xl0 5 cells, e.g., about 2xl0 5 cells lymphocytes are used.
  • lymphocytes can be used at a concentration from about O.lxlO 6 cells/ml to about IxlO 6 cells/ml, e.g., about 0.2xl0 6 cells/ml to about 0.4xl0 6 cells/ml.
  • Lymphocytes for use in the presently disclosed methods include any cell that can interact with an antigen complexed with a major histocompatibility complex (MHC) on the surface of a cell.
  • MHC major histocompatibility complex
  • the lymphocytes can comprise T cells.
  • T cells at least about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99% of the lymphocytes are T cells.
  • the lymphocytes are T cells, e.g., CD4+ T cells.
  • the lymphocytes can further include antigen-presenting cells (APCs).
  • APCs antigen-presenting cells
  • the T cells are CD8-. In certain embodiments, the T cells are CD4+. In certain embodiments, the T cells are CD4+ CD8-. For example, but not by way of limitation, at least about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99% of the T cells are CD8-, CD4+ or CD4+ CD8- cells. In certain embodiments, at least about 20%, e.g., at least about 30%, of the T cells are CD8-, CD4+ or CD4+ CD8- cells.
  • Non-limiting sources of lymphocytes include peripheral blood mononuclear cells (PBMCs) isolated from donors.
  • PBMCs are isolated from a sample of a donor, e.g, from a blood sample of the donor.
  • PBMCs can be isolated from a sample of a donor by any method known in the art, e.g, by a density gradient centrifugation.
  • PBMCs are initially isolated from a sample of a donor and then subjected to a CD8 negative selection to isolate and/or select CD8- cells, e.g., CD8- T cells.
  • PBMCs can be a PBMC cell line.
  • the lymphocytes can comprise T cells, e.g., CD8- T cells, CD4+ T cells or CD4+ CD8- T cells.
  • the lymphocytes can be differentiated from stem cells or iPSC cells.
  • the lymphocytes can be T cells, e.g., CD8- T cells, CD4+ T cells or CD4+ CD8- T cells, that are differentiated from stem cells or iPSC cells.
  • APCs including, but not limited to, dendritic cells, macrophages and B cells
  • PBMCs can be isolated from PBMCs, and used in methods that include culturing the APCs in the presence of a composition of interest and/or T cells, as discussed below.
  • the lymphocytes obtained from PBMCs can include T cells, e.g., CD8- T cells, CD4+ T cells or CD4+ CD8- T cells, and APCs for use in the methods disclosed herein.
  • the methods of the present disclosure can comprise isolating CD14+ cells from PBMCs prior to exposure to the composition.
  • CD14+ cells can be isolated and induced, e.g., by exposure to GM-CSF and/or IL4, to differentiate into APCs, e.g., dendritic cells, e.g., immature dendritic cells, and subsequently cultured in the presence of the composition to generate stimulated APCs, e.g, stimulated mature dendritic cells.
  • the APCs e.g., immature dendritic cells
  • the APCs can be cultured in the presence of the composition and GM-CSF, IL4, TNF-a, IL-ip, IL6 and/or PGE2 to generate stimulated APCs, e.g., stimulated mature dendritic cells.
  • the stimulated APCs e.g., monocyte-derived dendritic cells
  • T cells e.g., CD4+ T cells and/or CD4+ CD8- T cells, and T cell activation can be assayed.
  • the T cells can be isolated from PBMCs, as discussed below.
  • APCs and T cells can be isolated from the same PBMC sample or population. In certain embodiments, APCs and T cells can be isolated from the same donor. In certain embodiments, culturing of the APCs with the composition in the absence of T cells followed by the subsequent culturing of APCs with T cells can avoid potential assay interference due to the direct activation of the T cell by the composition.
  • the lymphocytes are cultured with about 10 pg/ul to about 1,000 pg/ml of the composition, e.g., about 100 pg/ml of the composition.
  • the composition can be used at a concentration from about 30 pg/ml to about 1,000 pg/ml, from about 40 pg/ml to about 1,000 pg/ml, from about 50 pg/ml to about 1,000 pg/ml, from about 60 pg/ml to about 1,000 pg/ml, from about 70 pg/ml to about 1,000 pg/ml, from about 80 pg/ml to about 1,000 pg/ml, from about 90 pg/ml to about 1,000 pg/ml, from about 10 pg/ml to about 900 pg/ml, from about 10 pg/ml to about 800 pg/ml, from about 10 pg/ml to about 700
  • the lymphocytes are cultured with about 100 pg/ml of the composition.
  • the lymphocytes can be T cells, e.g., CD4+ T cells and/or CD4+ CD8- T cells, which are cultured with the composition.
  • the lymphocytes can include T cells and APCs, which are cultured with the composition.
  • the method can include culturing APCs, e.g., dendritic cells, macrophages and/or B cells, in the presence of the composition of interest and the lymphocytes, e.g., T cells.
  • the method can include culturing dendritic cells in the presence of the composition of interest and the lymphocytes, e.g., T cells.
  • the methods can include culturing isolated APCs, e.g., dendritic cells, macrophages and/or B cells, in the presence of the composition of interest but in the absence of T cells.
  • the methods can include culturing isolated dendritic cells in the presence of the composition of interest but in the absence of T cells.
  • the method can further include determining the percentage of the stimulated lymphocytes that are CD4+ and express: (i) CD134; (ii) CD137; or (iii) CD134 and CD137. In certain embodiments, the method can include determining the percentage of the unstimulated lymphocytes that are CD4+ and express: (i) CD134; (ii) CD137; or (iii) CD134 and CD137. In certain embodiments, the method can include determining whether such cells are live.
  • determining the amount of unstimulated and/or stimulated lymphocytes includes (i) contacting the lymphocytes, e.g., T cells, with one or more detection agent that bind to the CD4, CD 134 and/or CD137 and (ii) determining the number of lymphocytes, e.g., T cells, that are bound to the one or more detection agents.
  • the detection agent for use in the methods disclosed herein is an antibody (also referred to herein as “a detection antibody”).
  • the detection agent specifically binds to the polypeptide analyzed by the disclosed methods, e.g., the detection agent specifically binds to an epitope present on the polypeptide or fragment thereof.
  • the detection agent is an antibody that binds to CD4.
  • the detection agent is an antibody that binds to CD134.
  • the detection agent is an antibody that binds to CD137.
  • the detection agents used in the assay methods disclosed herein can be used at a concentration from about 0.05 pg/ml to about 5 pg/ml, e.g., about 1 pg/ml.
  • the detection agents e.g., detection antibodies
  • labeled include, but are not limited to, labels or moieties that are detected directly, such as fluorescent, chromophoric, electron-dense, chemiluminescent, and radioactive labels, as well as moieties, such as enzymes or ligands, that are detected indirectly, e.g., through an enzymatic reaction or molecular interaction.
  • Non-limiting examples of labels include the radioisotopes 32 P, 14 C, 125 I, 3 H and 131 I, fluorophores such as rare earth chelates or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, luciferases, e.g., firefly luciferase and bacterial luciferase (see U.S. Patent No.
  • the detection agent e.g., antibody
  • the detection agent is labeled with a fluorophore.
  • determining the number of cells, e.g., lymphocytes, labeled by the one or more detection agents is performed by any method that is able to detect the detection agent.
  • the detection agent can be detected by monitoring the label of the detection agent, e.g., the fluorescent label.
  • determining the number of cells lymphocytes labeled by the one or more detection agents is performed by flow cytometry.
  • the method further includes calculating a stimulation index value.
  • the stimulation index value can be determined by dividing the percentage of stimulated lymphocytes with the percentage of unstimulated lymphocytes. Alternatively or additionally, the stimulation index value can be determined by outlier sum analysis or by linear regression. In certain embodiments, the stimulation index value can be determined by dividing the maximum value or average value of stimulated lymphocytes with the maximum value or average value of unstimulated lymphocytes.
  • the method can include comparing the stimulation index value to a reference stimulation index. In certain embodiments, when the stimulation index value is greater than the reference stimulation index value, the polypeptide has a greater propensity to elicit production of ADAs than the reference. Alternatively, when the stimulation index value of a polypeptide is less than the reference stimulation index value, the polypeptide has a lesser propensity to elicit production of ADAs than the reference, e.g., in the clinical setting.
  • the reference stimulation index is indicative of a known propensity to elicit the production of ADAs, e.g., in the clinical setting.
  • the reference stimulation index is from about 1.0 to about 4.0, e.g., from about 1.0 to about 3.0, from about 1.1 to about 2.0, from about 1.2 to about 2.0, from about 1.3 to about 2.0, from about 1.4 to about 2.0, from about 1.5 to about 2.0, from about 1.6 to about 2.0, from about 1.7 to about 2.0, from about 1.8 to about 2.0 or from about 1.8 to about 3.0.
  • the reference stimulation index is from about 1.5 to about 2.0.
  • the reference stimulation index is from about 1.6 to about 1.8.
  • the reference stimulation index value is about 1.6 or greater. In certain embodiments, the reference stimulation index value is about 1.7 or greater. In certain embodiments, the reference stimulation index value is about 1.8 or greater. In certain embodiments, the reference stimulation index value is about 1.9 or greater. In certain embodiments, the reference stimulation index value is about 2.0 or greater. In certain embodiments, the reference stimulation index value is about 2.1 or greater. In certain embodiments, the reference stimulation index value is about 2.2 or greater. In certain embodiments, the reference stimulation index value is about 2.3 or greater. In certain embodiments, the reference stimulation index value is about 2.4 or greater. In certain embodiments, the reference stimulation index value is about 2.5 or greater. In certain embodiments, the reference stimulation index value is about 2.6 or greater.
  • the reference stimulation index value is about 2.7 or greater. In certain embodiments, the reference stimulation index value is about 2.8 or greater. In certain embodiments, the reference stimulation index value is about 2.9 or greater. In certain embodiments, the reference stimulation index value is about 3.0 or greater.
  • the reference stimulation index is a value produced by a composition (e.g., a reference composition) that has a low propensity to elicit production of AD As, e.g. , in the clinical setting.
  • a composition e.g., a reference composition
  • the reference composition can be an antibody that has been shown to not elicit production of AD As in a clinical setting or has a low propensity to elicit production of ADAs in a clinical setting.
  • the reference stimulation index can be the stimulation index of a composition (e.g., reference composition) that has been shown to elicit production of ADAs.
  • the reference composition can be an antibody that has been shown to elicit production of ADAs in a clinical setting.
  • the reference composition can be an antibody disclosed in any one of the Figures and/or examples.
  • the reference stimulation index can be the stimulation index of the parent antibody.
  • the reference stimulation index can be the stimulation index of one of the parent antibodies.
  • methods of the present disclosure can include (i) culturing lymphocytes in the presence of the composition to generate stimulated lymphocytes; (ii) culturing lymphocytes in the absence of the composition to generate unstimulated lymphocytes; (iii) determining the percentage of the stimulated lymphocytes that are CD4+ and express: (a) CD134; (b) CD137; or (c) CD134 and CD137; (iv) determining the percentage of the unstimulated lymphocytes that are CD4+ and express: (a) CD134; (b) CD137; or (c) CD134 and CD137; and (v) calculating a stimulation index value.
  • the composition when the stimulation index value in (v) is greater than or equal to a reference stimulation index value then the composition has a greater propensity to elicit antibodies specific to said composition. In certain embodiments, when the stimulation index value in (v) is less than the reference stimulation index value then the composition has a lesser propensity to elicit antibodies specific to said composition.
  • methods of the present disclosure can include culturing APCs, e.g., CD14+ APCs, in the presence of the composition and in the absence of CD4+ lymphocytes, e.g., T cells.
  • the APCs are isolated from PBMCs prior to the culturing of such APCs with the composition.
  • the methods can also include culturing APCs, e.g., isolated APCs, in the absence of the composition and in the absence of CD4+ lymphocytes, e.g., T cells.
  • the method can further include co-culturing CD4+ lymphocytes, e.g., T cells, with the APCs that have been previously cultured in the presence of the composition to produce stimulated CD4+ lymphocytes, e.g., stimulated T cells.
  • the method can further include co-culturing CD4+ lymphocytes, e.g., T cells, with the APCs that have been previously cultured in the absence of the composition to produce unstimulated CD4+ lymphocytes, e.g., unstimulated T cells.
  • the CD4+ lymphocytes, e.g., CD4+ T cells and/or CD4+ CD8- T cells are isolated from PBMCs.
  • the T cells and the APCs are isolated from the same PBMC population.
  • the T cells e.g, CD4+ T cells
  • the APCs e.g, CD14+ APCs
  • the APCs are dendritic cells.
  • a method of the present disclosure can include (i) culturing APCs in the presence of the composition to produce APCs that display an antigen of the composition; (ii) culturing APCs in the absence of the composition to produce APCs that do not present an antigen of the composition; (iii) co-culturing the APCs of (i) with CD4+ lymphocytes; (iv) co-culturing the APCs of (ii) with CD4+ lymphocytes; (v) determining the percentage of the CD4+ lymphocytes from the co-culture of (iii) that are CD4+ and express: (a) CD134; (b) CD137; or (c) CD134 and CD137; and (vi) determining the percentage of the T cells from the co-culture of (iv) that are CD4+ and express: (a) CD134; (b) CD137; or (c) CD134 and CD137; and (vii) calculating a stimulation index value.
  • the method can further include comparing the stimulation index value of (vii) to a reference stimulation index value. In certain embodiments, when the stimulation index value in (vii) is greater than or equal to the reference stimulation index value then the composition has a greater propensity to elicit antibodies specific to said composition. In certain embodiments, when the stimulation index value in (vii) is less than the reference stimulation index value then the composition has a lesser propensity to elicit antibodies specific to said composition.
  • the method can include analyzing the composition with lymphocytes obtained from more than one donor.
  • a method of the present disclosure can include analyzing the propensity of a composition to elicit production of ADAs by (i) separately culturing lymphocytes derived from individual donors with the composition of interest to generate stimulated lymphocytes and (ii) separately culturing lymphocytes derived from individual donors in the absence of the composition to generate unstimulated lymphocytes.
  • the lymphocytes used in connection with the methods of the present disclosure can be derived from at least 2 or more, at least 3 or more, at least 4 or more, at least 5 or more, at least 6 or more, at least 7 or more, at least 8 or more, at least 9 or more, at least 10 or more, at least 15 or more, at least 20 or more, at least 25 or more, at least 30 or more, at least 35 or more, at least 40 or more or at least 45 or more individual donors.
  • lymphocytes e.g., PBMCs or APCs
  • lymphocytes derived from about 20 to about 50 donors can be used, e.g., separately cultured with the composition of interest. In certain embodiments, lymphocytes derived from about 35 to about 45 donors can be separately used, e.g., cultured with the composition of interest. In certain embodiments, the lymphocytes derived from individual donors can be T cells, e.g., CD4+ T cells and/or CD4+ CD8- T cells, which are cultured with the composition. In certain embodiments, the lymphocytes derived from individual donors can include T cells and APCs, which are cultured with the composition.
  • the method can include culturing APCs, e.g., dendritic cells, macrophages and/or B cells, in the presence of the composition of interest and the lymphocytes derived from individual donors, e.g., T cells.
  • APCs e.g., dendritic cells, macrophages and/or B cells
  • the method can further include (a) determining the percentage of the stimulated lymphocytes from the individual donors that are CD4+ and express: (i) CD134; (ii) CD137; or (iii) CD134 and CD137, and (b) determining the percentage of the unstimulated lymphocytes from the donors that are CD4+ and express: (i) CD134; (ii) CD137; or (iii) CD134 and CD137.
  • the method can further include (a) determining the percentage of the CD4+ lymphocytes cultured with the stimulated APCs that express: (i) CD134; (ii) CD137; or (iii) CD134 and CD137, and (b) determining the percentage of the CD4+ lymphocytes cultured with the unstimulated APCs that express: (i) CD 134; (ii) CD137; or (iii) CD134 and CD137.
  • stimulation index values for each of the individual donors can be determined, e.g., by dividing the percentage of stimulated lymphocytes of an individual donor with the percentage of unstimulated lymphocytes of that individual donor.
  • stimulation index values for each of the individual donors can be determined, e.g., by dividing the percentage of CD4+ cells cultured with the stimulated APCs that express: (i) CD134; (ii) CD137; or (iii) CD134 and CD137 of an individual donor with the percentage of CD4+ lymphocytes cultured with the unstimulated APCs that express: (i) CD134; (ii) CD137; or (iii) CD134 and CD137 of that individual donor.
  • the method also includes calculating a number of reactive lymphocyte donors where the donors’ stimulation index value is greater than or equal to a reference value stimulation index value and the number of non-reactive lymphocyte donors where the donors’ stimulation index value is less than the reference stimulation index value.
  • the composition has a high propensity to elicit the production of antibodies if the number of reactive donors is greater than 30% of the total number of donors. Alternatively, the composition has a low propensity to elicit the production of antibodies if the number of reactive donors is less than 20% of the total number of donors.
  • the present disclosure further provides methods for determining the propensity of a neoantigen to elicit an immune response to the neoantigen.
  • the method includes (a) culturing lymphocytes in the presence of the neoantigen to generate stimulated lymphocytes; (b) culturing lymphocytes in the absence of the neoantigen to generate unstimulated lymphocytes; (c) determining the percentage of the stimulated lymphocytes that are CD4+ and express: (i) CD134; (ii) CD137; or (iii) CD134 and CD 137; (d) determining the percentage of the unstimulated lymphocytes that are CD4+ and express: (i) CD134; (ii) CD137; or (iii) CD134 and CD137; and (e) calculating a stimulation index value (e.g., by dividing the percentage of stimulated lymphocytes determined in (c) with the percentage of unstimulated lymphocytes determined in (d)).
  • the neoantigen when the stimulation index value in (e) is greater than or equal to a reference stimulation index value then the neoantigen has a greater propensity to elicit an immune response specific to said neoantigen and when the stimulation index value in (e) is less than the reference stimulation index value then the neoantigen has a lesser propensity to elicit an immune response specific to said neoantigen.
  • the neoantigen is in a complex with an MHC molecule, e.g., MHC class II molecule.
  • the neoantigen can be complexed with an MHC class II molecule
  • the present disclosure further provides methods for determining the propensity of a neoantigen to elicit an immune response to the neoantigen.
  • the method includes (a) culturing APCs in the presence of the neoantigen to generate stimulated APCs; (b) culturing APCs in the absence of the neoantigen to generate unstimulated APCs; (c) separately culturing the stimulated APCs with CD4+ lymphocytes and the unstimulated APCs with CD4+ lymphocytes; (d) determining the percentage of the CD4+ lymphocytes cultured with the stimulated APCs that express: (i) CD 134; (ii) CD 137; or (iii) CD 134 and CD 137; (e) determining the percentage of the CD4+ lymphocytes cultured with the unstimulated APCs that express: (i) CD134; (ii) CD137; or (iii) CD134 and CD137; and
  • the neoantigen when the stimulation index value in (f) is greater than or equal to a reference stimulation index value then the neoantigen has a greater propensity to elicit an immune response specific to said neoantigen and when the stimulation index value in (f) is less than the reference stimulation index value then the neoantigen has a lesser propensity to elicit an immune response specific to said neoantigen.
  • the neoantigen is in a complex with an MHC molecule, e.g., MHC class II molecule.
  • the neoantigen can be complexed with an MHC class II molecule.
  • the composition that is assayed using any of the methods disclosed herein can comprise a polypeptide or a fragment of the polypeptide, e.g., a peptide.
  • the composition can comprise an antibody or a fragment thereof, e.g., a human, humanized or chimeric antibody.
  • the composition can comprise an antibody-drug conjugate (ADC).
  • the antibody can be a single domain antibody.
  • the composition can comprise a neoantigen or a complex containing a neoantigen.
  • the composition is an antibody that is specific for a neoantigen.
  • composition analyzed by the methods disclosed herein can comprise a peptide or protein or fragment thereof.
  • the composition can be a protein or a fragment thereof.
  • the protein can have a molecular weight of at least about 15-100 kD, e.g., closer to about 15 kD.
  • the protein can include at least about 50, about 60, about 70, about 80, about 90, about 100, about 200, about 300, about 400, about 500 amino acids, about 1,000 amino acids, about 1,500 amino acids, about 2,000 amino acids, about 2,500 amino acids, about 3,000 amino acids, about 35,000 amino acids or about 40,000 amino acids.
  • proteins include all proteins, and, in general proteins that contain one or more disulfide bonds, including multi-chain polypeptides comprising one or more inter- and/or intrachain disulfide bonds.
  • the proteins e.g., antibodies
  • the composition can be a peptide.
  • the peptides can be composed of about 3-50 amino acid residues.
  • the 3-50 amino acid residues can be continuous within a larger polypeptide or protein or can be a group of 3-50 residues that are discontinuous in a primary sequence of a larger polypeptide or protein but that are spatially near in three-dimensional space.
  • the peptide can be a part of a peptide, a part of a full protein or polypeptide and can be released from that protein or polypeptide by proteolytic treatment or can remain part of the protein or polypeptide.
  • the peptide can have a length of 3 residues or more, a length of 4 residues or more, a length of 5 residues or more, 6 residues or more, 7, residues or more, 8 residues or more, 9 residues or more, 10 residues or more, 11 residues or more,
  • the peptide has a length of 3-50 residues, 5-50 residues, 3-45 residues, 5-45 residues, 3-40 residues, 5-40 residues, 3-35 residues, 5-35 residues, 3-30 residues, 5-30 residues, 3-25 residues, 5-25 residues, 3-20 residues, 5-20 residues, 3-15 residues, 5-15 residues, 3-10 residues, 3-10 residues, 5-10 residues, 10-15 residues, 15-20 residues, 20-25 residues, 25- 30 residues, 30-35 residues, 35-40 residues, 40-45 residues or 45-50 residues. In certain embodiments, the peptide has a length of about 5 to about 30 residues.
  • the peptide has a length of 9 residues. In certain embodiments, the peptide has a length of 10 residues. In certain embodiments, the peptide has a length of 11 residues. In certain embodiments, the peptide has a length of 12 residues. In certain embodiments, the peptide has a length of 13 residues. In certain embodiments, the peptide has a length of 14 residues. In certain embodiments, the peptide has a length of 15 residues. In certain embodiments, the peptide has a length of 16 residues. In certain embodiments, the peptide has a length of 17 residues. In certain embodiments, the peptide has a length of 18 residues.
  • the peptide has a length of 99 residues. In certain embodiments, the peptide has a length of 20 residues. In certain embodiments, the peptide has a length of 21 residues. In certain embodiments, the peptide has a length of 22 residues. In certain embodiments, the peptide has a length of 23 residues. In certain embodiments, the peptide has a length of 24 residues. In certain embodiments, the peptide has a length of 25 residues. In certain embodiments, the peptide has a length of 26 residues. In certain embodiments, the peptide has a length of 27 residues. In certain embodiments, the peptide has a length of 28 residues.
  • the peptide has a length of 29 residues. In certain embodiments, the peptide, e.g., peptide, has a length of 30 residues. In certain embodiments, the peptide has a length of 31 residues. In certain embodiments, the peptide has a length of 32 residues. In certain embodiments, the peptide has a length of 33 residues. In certain embodiments, the peptide has a length of 34 residues. In certain embodiments, the peptide has a length of 35 residues. In certain embodiments, the peptide has a length of 36 residues. In certain embodiments, the peptide has a length of 37 residues. In certain embodiments, the peptide has a length of 38 residues.
  • the peptide has a length of 39 residues. In certain embodiments, the peptide has a length of 40 residues. In certain embodiments, the peptide has a length of 41 residues. In certain embodiments, the peptide has a length of 42 residues. In certain embodiments, the peptide has a length of 43 residues. In certain embodiments, the peptide has a length of 44 residues. In certain embodiments, the peptide has a length of 45 residues. In certain embodiments, the peptide has a length of 46 residues. In certain embodiments, the peptide has a length of 47 residues. In certain embodiments, the peptide has a length of 48 residues. In certain embodiments, the peptide has a length of 49 residues. In certain embodiments, the peptide has a length of 50 residues.
  • the protein or fragment thereof can be an antibody or an antigen-binding fragment thereof, as disclosed herein.
  • the peptide can be a neoantigen, as disclosed herein.
  • Antibody fragments include, but are not limited to, Fab, Fab’, Fab’-SH, F(ab’)2, Fv, and scFv fragments, and other fragments described below.
  • Fab fragment antigen binding protein
  • Fab fragment antigen binding protein
  • Fab fragment antigen binding protein
  • Fab fragment antigen binding protein
  • Fab fragment antigen binding protein
  • Fab fragment antigen binding protein
  • Antibody fragments can be made by various techniques including, but not limited to, proteolytic digestion of an intact antibody as well as production by recombinant host cells (e.g., E. coll or phage), as described herein.
  • a composition analyzed by the methods disclosed herein can be a diabody.
  • Diabodies are antibody fragments comprising two antigenbinding sites that may be bivalent or bispecific. See, for example, EP 404097; WO 1993/01161; Hudson et al., Nat. Med. 9: 129-134 (2003); and Hollinger et al., Proc. Natl. Acad. Set. USA 90: 6444-6448 (1993).
  • Triabodies and tetrabodies which are also described in Hudson et al., Nat. Med. 9: 129-134 (2003) can be analyzed by the disclosed methods.
  • the antibody analyzed by the disclosed methods can be a single-domain antibody.
  • Single-domain antibodies are antibody fragments that comprise all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody.
  • a single-domain antibody is a human single-domain antibody (Domantis, Inc., Waltham, MA; see, e.g., U.S. Patent No. 6,248,516 Bl). Additional non-limiting examples of single-domain antibodies are disclosed in lezzi et al., Front Immunol. 9:273 (2016), the contents of which are incorporated by reference herein in their entirety.
  • the antibody is a hybribody (Hybrigenics Services, Cambridge, MA).
  • a composition analyzed by the methods disclosed herein comprises a chimeric antibody, e.g., a humanized antibody.
  • a chimeric antibody e.g., a humanized antibody.
  • the presently disclosed methods can be used to identify chimeric versions of an antibody that have a low or lower propensity to elicit productions of AD As, e.g., compared to the parent antibody or other chimeric versions of the antibody.
  • methods of the present disclosure can be used to identify chimeric antibodies that have a low propensity to elicit production of AD As.
  • a chimeric antibody includes a non-human variable region (e.g., a variable region derived from a mouse, rat, hamster, rabbit or non-human primate, such as a monkey) and a human constant region.
  • a chimeric antibody can be a “class switched” antibody in which the class or subclass has been changed from that of the parent antibody. Chimeric antibodies include antigen-binding fragments thereof.
  • a chimeric antibody can be a humanized antibody.
  • a non-human antibody is humanized to reduce immunogenicity to humans, while retaining the specificity and affinity of the parental non-human antibody.
  • a humanized antibody comprises one or more variable domains in which CDRs, e.g., CDRs, (or portions thereof) are derived from a non-human antibody, and FRs (or portions thereof) are derived from human antibody sequences.
  • a humanized antibody optionally will also comprise at least a portion of a human constant region.
  • some FR residues in a humanized antibody are substituted with corresponding residues from a non-human antibody (e.g., the antibody from which the CDR residues are derived), e.g., to restore or improve antibody specificity or affinity.
  • a non-human antibody e.g., the antibody from which the CDR residues are derived
  • a composition analyzed by the methods disclosed herein can be a human antibody.
  • the presently disclosed methods can be used to identify chimeric versions of an antibody that has a low or lower propensity to elicit productions of human antibodies that have a low propensity to elicit production of AD As.
  • a composition analyzed by the methods disclosed herein can comprise an antibody or fragment thereof isolated by screening combinatorial libraries for antibodies with the desired activity or activities.
  • the presently disclosed methods can be used to identify a library-derived antibody that has a low or lower propensity to elicit productions of AD As, e.g., as compared other library-derived antibodies that possess the desired binding characteristics and/or bind to the same antigen.
  • Antibodies or antibody fragments isolated from human antibody libraries are considered human antibodies or human antibody fragments herein.
  • a composition analyzed by the methods disclosed herein can comprise a multispecific antibody, e.g., a bispecific antibody.
  • Multispecific antibodies are monoclonal antibodies that have binding specificities for at least two different epitopes.
  • Bispecific antibodies can be prepared as full-length antibodies or antibody fragments.
  • the presently disclosed methods can be used to identify multi specific antibodies that have a low or lower propensity to elicit productions of AD As, e.g., compared to other multispecific antibodies that bind the same epitopes.
  • methods of the present disclosure can be used to identify multispecific antibodies that have a low propensity to elicit production of ADAs.
  • the presently disclosed methods can be used to identify multispecific antibodies, e.g., bispecific antibodies, that have a low or lower propensity to elicit productions of ADAs, e.g., compared to other antibodies, e.g., monospecific or multispecific antibodies, that bind at least one of the same epitopes as the multispecific antibody.
  • multispecific antibodies e.g., bispecific antibodies
  • ADAs e.g., compared to other antibodies, e.g., monospecific or multispecific antibodies, that bind at least one of the same epitopes as the multispecific antibody.
  • a composition analyzed by the methods disclosed herein can comprise a bispecific antibody that has a binding specificity for T cells.
  • the bispecific antibody can comprise a first antigen-binding domain that binds to T cells, and a second binding specificity for a second epitope, e.g., an epitope that is not present on T cells.
  • Engineered antibodies with three or more functional antigen binding sites can also be analyzed by the disclosed methods (see, e.g., US 2006/0025576A1).
  • a composition analyzed by the methods disclosed herein can comprise an immunoconjugate, e.g., an immunoconjugate comprising an antibody conjugated to one or more cytotoxic agents, such as chemotherapeutic agents or drugs, growth inhibitory agents, toxins (e.g, protein toxins, enzymatically active toxins of bacterial, fungal, plant or animal origin, or fragments thereof) or radioactive isotopes.
  • cytotoxic agents such as chemotherapeutic agents or drugs, growth inhibitory agents, toxins (e.g, protein toxins, enzymatically active toxins of bacterial, fungal, plant or animal origin, or fragments thereof) or radioactive isotopes.
  • toxins e.g, protein toxins, enzymatically active toxins of bacterial, fungal, plant or animal origin, or fragments thereof
  • radioactive isotopes e.g., an antibody or antigen-binding portion can be functionally linked (e.g, by chemical coupling, genetic fusion, non
  • an immunoconjugate is an antibody-drug conjugate (ADC) in which an antibody is conjugated to one or more drugs, including but not limited to a maytansinoid (see U.S. Patent Nos. 5,208,020, 5,416,064 and European Patent EP 0 425 235); an auristatin such as monomethylauristatin drug moi eties DE and DF (MMAE and MMAF) (see U.S. Patent Nos. 5,635,483 and 5,780,588, and 7,498,298); a dolastatin; a calicheamicin or derivative thereof (see U.S. Patent Nos.
  • ADC antibody-drug conjugate
  • drugs including but not limited to a maytansinoid (see U.S. Patent Nos. 5,208,020, 5,416,064 and European Patent EP 0 425 235); an auristatin such as monomethylauristatin drug moi eties DE and DF (MMAE and MMAF) (see U
  • an immunoconjugate comprises an antibody conjugated to an enzymatically active toxin or fragment thereof, including but not limited to diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha- sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes.
  • an enzymatically active toxin or fragment thereof including but not limited to diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Ps
  • an immunoconjugate comprises an antibody conjugated to a radioactive atom to form a radioconjugate.
  • a variety of radioactive isotopes are available for the production of radioconjugates. Non-limiting examples include At 211 , 1 131 , 1 125 , Y 90 , Re 186 , Re 188 , Sm 153 , Bi 212 , P 32 , Pb 212 and radioactive isotopes of Lu.
  • the radioconjugate When used for detection, it can include a radioactive atom for scintigraphic studies, for example tc99m or 1123, or a spin label for nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging, mri), such as iodine-123 again, iodine-131, indium-i l l, fluorine-19, carbon-13, nitrogen-15, oxygen- 17, gadolinium, manganese or iron.
  • NMR nuclear magnetic resonance
  • Conjugates of an antibody and cytotoxic agent can be made using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP), succinimidyl-4-(N-maleimidomethyl) cyclohexane- 1 -carboxylate (SMCC), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HC1), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis- diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as toluene 2,6-diisocyanate), and bis-active fluorine compounds (such
  • a ricin immunotoxin can be prepared as described in Vitetta et al., Science 238: 1098 (1987).
  • Carbon- 14-labeled 1- isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026.
  • the linker can be a “cleavable linker” facilitating release of a cytotoxic drug in the cell.
  • an acid-labile linker, peptidase-sensitive linker, photolabile linker, dimethyl linker or disulfide-containing linker (Chari et al., Cancer Res. 52: 127-131 (1992); U.S. Patent No. 5,208,020) can be used.
  • immunoconjugates include, but are not limited to, such conjugates prepared with cross-linker reagents including, but not limited to, BMPS, EMCS, GMBS, HBVS, LC-SMCC, MBS, MPBH, SBAP, SIA, SIAB, SMCC, SMPB, SMPH, sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB, sulfo-SMCC, and sulfo-SMPB, and SVSB (succinimidyl-(4-vinylsulfone)benzoate) which are commercially available (e.g., from Pierce Biotechnology, Inc., Rockford, IL., U.S.A).
  • cross-linker reagents including, but not limited to, BMPS, EMCS, GMBS, HBVS, LC-SMCC, MBS, MPBH, SBAP,
  • a composition analyzed by the methods disclosed herein can comprise an antibody variant of a previously disclosed antibody.
  • methods of the present disclosure can be used to identify antibodies that are variants of previously disclosed antibodies that have a lower propensity to elicit productions of AD As, e.g., than the parent antibody.
  • amino acid substitutions can be introduced into an antibody of interest and the antibody variants can be screened for immunogenicity by using the disclosed methods.
  • the antibody variant can be amino acid sequence variants of an antibody, e.g., prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody or by peptide synthesis.
  • modifications include, but are not limited to, deletions from, and/or insertions into and/or substitutions of residues within the amino acid sequences of the antibody.
  • Sites of interest for such variation include, but are not limited to, the CDRs, and FRs. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final antibody, i.e., modified, possesses the desired characteristics, e.g., antigen-binding.
  • an antibody variant can be an antibody that has been altered to increase or decrease the extent to which the antibody is glycosylated.
  • the addition or deletion of glycosylation sites of an antibody can be accomplished by altering the amino acid sequence such that one or more glycosylation sites is created or removed.
  • an antibody analyzed by the methods disclosed herein is an Fc region variant.
  • the Fc region variant can include a human Fc region sequence (e.g., a human IgGl, IgG2, IgG3 or IgG4 Fc region) comprising an amino acid modification (e.g., a substitution) at one or more amino acid positions.
  • an antibody variant can be a cysteine engineered antibody, e.g., “thioMAb,” in which one or more residues of an antibody are substituted with cysteine residues.
  • the substituted residues occur at accessible sites of the antibody.
  • reactive thiol groups are thereby positioned at accessible sites of the antibody and may be used to conjugate the antibody to other moieties, such as drug moieties or linker-drug moieties, to create an immunoconjugate, as described further herein.
  • any one or more of the following residues may be substituted with cysteine: V205 (Kabat numbering) of the light chain; Al 18 (EU numbering) of the heavy chain; and S400 (EU numbering) of the heavy chain Fc region.
  • cysteine V205 (Kabat numbering) of the light chain; Al 18 (EU numbering) of the heavy chain; and S400 (EU numbering) of the heavy chain Fc region.
  • Cysteine engineered antibodies can be generated as described, e.g., in U.S. Patent No. 7,521,541.
  • a composition analyzed by the methods disclosed herein can comprise a neoantigen.
  • Neoantigens are antigens that are not associated with normal tissue or organs, and are generally derived from a genetic mutation, e.g., an insertion/deletion, a gene fusion, a frameshift mutation, a single nucleotide mutation, or a combination of the foregoing.
  • the neoantigen is a tumor neoantigen (also referred to as a tumor-specific antigen or TSA).
  • TSA tumor-specific antigen
  • T cells e.g., CD8 + and/or CD4 + T cells
  • Binding of such tumor neoantigens presented on APCs by T cells is one way in which an immune response can be mounted against the tumor associated with the tumor neoantigen. See, e.g. , Jiang et al., J. of Hematology & Oncology 12(93) (2019), the contents of which are incorporated by reference herein.
  • the neoantigen can be analyzed in the context of a complex.
  • the neoantigen can be in a complex with an MHC molecule, e.g., an MHC class I or II molecule.
  • the neoantigen can be in a complex with an MHC class II molecule.
  • a neoantigen for use in the present disclosure can be identified by any method known in the art.
  • a neoantigen can be identified by next-generation sequencing and/or in silico modeling. See, e.g., Garcia-Garijo et al., Front Immunol. 10: 1392 (2019), the contents of which are incorporated by reference herein.
  • a neoantigen identified by such methods can be analyzed in the presently disclosed methods to determine the propensity of the neoantigen to elicit an immune response specific to the neoantigen.
  • kits containing materials useful for performing the methods disclosed herein includes a container containing lymphocytes and/or a container containing one or more agents for detecting a marker, e.g., CD4, CD 134 and/or CD137, described herein.
  • suitable containers include bottles, test tubes, vials and microtiter plates.
  • the containers can be formed from a variety of materials such as glass or plastic.
  • the kit can include one or more containers containing one or more lymphocytes.
  • the kit can include at least one container containing PBMCs, lymphocytes, APCs and/or T cells.
  • the kit can include at least one container that includes CD8- T cells, CD4+ T cells and/or CD4+ CD8- T cells.
  • a kit of the present disclosure includes lymphocytes derived from one or more donors in one or more containers.
  • a kit of the present disclosure can further include one or more agents for detecting one or more markers disclosed herein, e.g., CD 134 and/or CD 137 antibodies.
  • the kit further includes a package insert that provides instructions for using the components provided in the kit.
  • a kit of the present disclosure can include a package insert that provides instructions for using the lymphocytes and/or agents in the disclosed methods.
  • the kit can include other materials desirable from a commercial and user standpoint, including other buffers, diluents and filters.
  • the kit can include materials for collecting and/or processing blood samples, e.g., to isolate lymphocytes from a sample.
  • the presently disclosed subject matter provides a method for determining the propensity of a composition to elicit the production of antibodies specific to said composition relative to a reference propensity, comprising: (a) culturing lymphocytes in the presence of the composition to generate stimulated lymphocytes;
  • (e) calculating a stimulation index value; wherein when the stimulation index value in (e) is greater than or equal to a reference stimulation index value then the composition has a greater propensity to elicit antibodies specific to said composition and when the stimulation index value in (e) is less than the reference stimulation index value then the composition has a lesser propensity to elicit antibodies specific to said composition.
  • A3 The foregoing method of any one of A-A2, wherein the stimulation index value is determined by dividing the percentage of stimulated lymphocytes determined in (c) with the percentage of unstimulated lymphocytes determined in (d).
  • A4 The foregoing method of any one of A-A3, wherein the stimulation index value is determined by outlier sum analysis or determined by linear regression.
  • lymphocytes comprise T cells.
  • A6 The foregoing method of A5, wherein at least 30% of the lymphocytes comprise T cells.
  • A7 The foregoing method of A5 or A6, wherein the T cells comprise CD8- T cells.
  • A8 The foregoing method of A7, wherein at least 10% of the T cells comprise CD8- T cells.
  • A9 The foregoing method of any one of A-A8, wherein the lymphocytes are obtained from a single donor.
  • A10 The foregoing method of any one of A-A8, wherein the lymphocytes are obtained from about 20 donors to about 50 donors.
  • lymphocytes are obtained from at least about 20 donors, at least about 25 donors, at least about 30 donors, at least about 35 donors, at least about 40 donors or at least about 45 donors.
  • A13 The foregoing method of any one of A-A12, wherein about 1x105 to about 1x107 lymphocytes are cultured with the composition.
  • A15 The foregoing method of any one of A-A14, wherein the composition comprises a peptide, a polypeptide or a small molecule compound.
  • Al 6 The foregoing method of Al 5, wherein the peptide or polypeptide comprises a neoantigen.
  • A18 The foregoing method of any one of A17, wherein the antibody is a human, humanized or chimeric antibody.
  • A19 The foregoing method of any one of A-A14, wherein the composition is an antibody-drug conjugate (ADC).
  • ADC antibody-drug conjugate
  • A20 The foregoing method of any one of A-A19, wherein the lymphocytes are cultured with the composition for about 48 hours or less.
  • A21 The foregoing method of any one of A-A20, wherein determining the percentage of the stimulated or the unstimulated lymphocytes that are CD4+ and express: (i) CD134; (ii) CD137; or (iii) CD134 and CD137 is performed by flow cytometry.
  • composition to elicit the production of antibodies specific to the composition, comprising:
  • lymphocytes comprise T cells.
  • B6 The foregoing method of B5, wherein at least 30% of the lymphocytes comprise T cells.
  • CD8- T cells B9. The foregoing method of any one of B-B8, wherein the lymphocytes are obtained from about 20 donors to about 50 donors.
  • lymphocytes are obtained from about 35 to about 45 donors.
  • Bl 1 The foregoing method of B9, wherein the lymphocytes are obtained from at least about 20 donors, at least about 25 donors, at least about 30 donors, at least about 35 donors, at least about 40 donors or at least about 45 donors.
  • composition comprises a peptide, a polypeptide or a small molecule compound.
  • Bl 7 The foregoing method of any one of B -Bl 6, wherein the lymphocytes are cultured with the composition for about 48 hours or less.
  • B18 The foregoing method of any one of B-B17, wherein determining the percentage of the stimulated or the unstimulated lymphocytes that are CD4+ and express: (i) CD134; (ii) CD137; or (iii) CD134 and CD137 is performed by flow cytometry.
  • the presently disclosed subject matter provides a method for determining the propensity of a neoantigen to elicit an immune response specific to said neoantigen relative to a reference antigen, comprising:
  • (e) calculating a stimulation index value; wherein when the stimulation index value in (e) is greater than or equal to a reference stimulation index value then the neoantigen has a greater propensity to elicit an immune response specific to said neoantigen and when the stimulation index value in (e) is less than the reference stimulation index value then the neoantigen has a lesser propensity to elicit an immune response specific to said neoantigen.
  • lymphocytes are obtained from at least about 20 donors, at least about 25 donors, at least about 30 donors, at least about 35 donors, at least about 40 donors or at least about 45 donors.
  • C13 The foregoing method of any one of C-C12, wherein the lymphocytes are cultured with the neoantigen for about 48 hours or less.
  • C14 The foregoing method of any one of C-C13, wherein determining the percentage of the stimulated or the unstimulated lymphocytes that are CD4+ and express: (i) CD134; (ii) CD137; or (iii) CD134 and CD137 is performed by flow cytometry.
  • the presently disclosed subject matter provides a kit for performing any one of the foregoing methods of A-C14.
  • the presently disclosed subject matter provides a method for determining the propensity of a composition to elicit the production of antibodies specific to said composition relative to a reference propensity, comprising:
  • APCs antigen presenting cells
  • (f) calculating a stimulation index value; wherein when the stimulation index value in (f) is greater than or equal to a reference stimulation index value then the composition has a greater propensity to elicit antibodies specific to said composition and when the stimulation index value in (f) is less than the reference stimulation index value then the composition has a lesser propensity to elicit antibodies specific to said composition.
  • E2 The foregoing method of E, wherein the reference stimulation index value is about 1.6 or greater, about 1.7 or greater, about 1.8 or greater, about 1.9 or greater, about 2.0 or greater, about 2.1 or greater, about 2.2 or greater, about 2.3 or greater, about 2.4 or greater, about 2.5 or greater, about 2.6 or greater, about 2.7 or greater, about 2.8 or greater, about 2.9 or greater or about 3.0 or greater.
  • E3 The foregoing method of any one of E-E2, wherein the stimulation index value is determined by dividing the percentage of CD4+ lymphocytes determined in (d) with the percentage of CD4+ lymphocytes determined in (e).
  • E4 The foregoing method of any one of E-E2, wherein the stimulation index value is determined by outlier sum analysis or determined by linear regression.
  • E6 The foregoing method of E5, wherein at least 10% of the CD4+ lymphocytes are CD8- T cells.
  • E10 The foregoing method of E8, wherein the APCs are obtained from at least about 20 donors, at least about 25 donors, at least about 30 donors, at least about 35 donors, at least about 40 donors or at least about 45 donors.
  • E17 The foregoing method of any one of E-E12, wherein the composition is an antibody-drug conjugate (ADC).
  • ADC antibody-drug conjugate
  • E19 The foregoing method of any one of E-E18, wherein determining the percentage of the CD4+ lymphocytes that express: (i) CD134; (ii) CD137; or (iii) CD134 and CD137 is performed by flow cytometry.
  • E20 The foregoing method of any one of E-E19, wherein determining the percentage of the CD4+ lymphocytes that express: (i) CD134; (ii) CD137; or (iii) CD134 and CD137 is performed by flow cytometry.
  • the presently disclosed subject matter provides a method for determining the propensity of a composition to elicit the production of antibodies specific to the composition, comprising:
  • F2 The foregoing method of F, wherein the reference stimulation index value is about 1.6 or greater, about 1.7 or greater, about 1.8 or greater, about 1.9 or greater, about 2.0 or greater, about 2.1 or greater, about 2.2 or greater, about 2.3 or greater, about 2.4 or greater, about 2.5 or greater, about 2.6 or greater, about 2.7 or greater, about 2.8 or greater, about 2.9 or greater or about 3.0 or greater.
  • F3 The foregoing method of any one of F-F2, wherein the stimulation index value is determined by dividing the percentage of CD4+ lymphocytes of an individual donor determined in (d) with the percentage of CD4+ lymphocytes of that individual donor determined in (e).
  • F6 The foregoing method of F5, wherein at least 10% of the CD4+ lymphocytes are CD8- T cells.
  • F7 The foregoing method of any one of F-F6, wherein the APCs are obtained from about 20 donors to about 50 donors.
  • F8 The foregoing method of F7, wherein the APCs are obtained from about 35 to about 45 donors.
  • F9 The foregoing method of F7, wherein the APCs are obtained from at least about 20 donors, at least about 25 donors, at least about 30 donors, at least about 35 donors, at least about 40 donors or at least about 45 donors.
  • F13 The foregoing method of F10, wherein the peptide or polypeptide comprises a neoantigen.
  • F14 The foregoing method of any one of F-F9, wherein the composition is an antibody-drug conjugate (ADC).
  • ADC antibody-drug conjugate
  • (f) calculating a stimulation index value; wherein when the stimulation index value in (f) is greater than or equal to a reference stimulation index value then the neoantigen has a greater propensity to elicit an immune response specific to said neoantigen and when the stimulation index value in (f) is less than the reference stimulation index value then the neoantigen has a lesser propensity to elicit an immune response specific to said neoantigen.
  • G1 The foregoing method of G, wherein the neoantigen is present in a complex with an MHC class II molecule.
  • G2 The foregoing method of G or Gl, wherein the reference stimulation index value is from about 1.0 to about 4.0, from about 1.0 to about 3.0 or from about 1.8 to about 3.0.
  • G3 The foregoing method of G or Gl, wherein the reference stimulation index value is about 1.6 or greater, about 1.7 or greater, about 1.8 or greater, about 1.9 or greater, about 2.0 or greater, about 2.1 or greater, about 2.2 or greater, about 2.3 or greater, about 2.4 or greater, about 2.5 or greater, about 2.6 or greater, about 2.7 or greater, about 2.8 or greater, about 2.9 or greater or about 3.0 or greater.
  • G4 The foregoing method of any one of G-G3, wherein the stimulation index value is determined by dividing the percentage of CD4+ lymphocytes determined in (d) with the percentage of CD4+ lymphocytes determined in (e).
  • G5. The foregoing method of any one of G-G3, wherein the stimulation index value is determined by outlier sum analysis or determined by linear regression.
  • G6. The foregoing method of any one of G-G5, wherein the CD4+ lymphocytes comprise CD8- T cells.
  • G7 The foregoing method of G6, wherein at least 10% of the CD4+ lymphocytes are CD8- T cells.
  • G8 The foregoing method of any one of G-G7, wherein the APCs are obtained from about 20 donors to about 50 donors.
  • G10 The foregoing method of G8, wherein the APCs are obtained from at least about 20 donors, at least about 25 donors, at least about 30 donors, at least about 35 donors, at least about 40 donors or at least about 45 donors.
  • Gi l The foregoing method of any one of G-G10, wherein the APCs are cultured with the neoantigen for about 48 hours or less.
  • Polypeptide-based therapeutics have the immunogenic potential to elicit the production of AD As.
  • such polypeptide-based therapeutics can be taken up and processed by antigen presenting cells such as dendritic cells to present fragments of the polypeptide-based therapeutic in complex with a class II MHC molecule on its surface. T cells subsequently interact with the fragments presented on the surface of the antigen presenting cells to elicit an immune reaction that results in the production of AD As by B cells.
  • FIG. 1 provides a schematic of the experimental details of the method.
  • Peripheral (PBMCs) were isolated from naive healthy donor’s blood by density gradient centrifugation using Uni-Sep blood separation tubes.
  • CD8+ cells were depleted using CD8 dynabeads (Thermo Fisher, Waltham, MA, catalog number: 11147D). It is noted that the assay also yielded good results when the PBMCs were cultured without CD8 depletion.
  • CD8- cells were then cultured with AIM-V medium (Thermo Fisher, Waltham, MA) with 10% human AB serum (Sigma Aldrich, catalog number: H3667) at a concentration of 2xl0 6 cells/mL in 24-well plates or 0.2-0.4xl0 6 cells in 96 well plate (Costar, catalog number 3526) and challenged with a final concentration of 100 pg/mL of the tested antibody. All samples are tested in triplicate. For each donor, responses to a negative control, consisting of medium- treated cells (referred to as the unstimulated cells), and positive control with Imject Mariculture KLH (mcKLH) (100 pg/ml) were also included.
  • AIM-V medium Thermo Fisher, Waltham, MA
  • human AB serum Sigma Aldrich, catalog number: H3667
  • Cells were placed in a 5% CO2 incubator at 37°C for 42-48 hours. Following 42-48 hours, cells were gently resuspended and 200 pl from each 24 well was transferred to a round bottom 96-well plate. CD4 activation was measured by the use of CD4, CD134, CD137 antibodies and live marker. The cells were analyzed by flow cytometry and plots are analyzed using FlowJo FACS analysis software (Tree Star, Inc.; Ashland, OR).
  • the stimulation index is calculated by dividing the mean and/or max percent of cells that were [live+CD4+CD134+CD137+ and live+CD4+CD134+CD137- and live+CD4+CD134- CD137+] of each treatment by the mean percent of cells that were [live+CD4+CD134+CD137+ and live+CD4+CD134+CD137- and live+CD4+CD134- CD137+] of the medium-only treated well (unstimulated cells) for each treatment.
  • Figure 2 shows FACS analysis of two different antibodies, AVASTIN® and bococizumab, that have different clinical ADA rates.
  • Bococizumab which has a high ADA rate, resulted in a higher number of cells that expressed CD4 activation markers compared to AVASTIN®, which has a low ADA rate.
  • HLA-DR and HLA-II blocking antibodies ( Figure 6A).
  • Figure 6A antibodies block the interaction of HLA-II to the TCR present on the surface of the T cell thereby blocking the activation of the T cell.
  • Figure 6B blocking HLA-DR and HLA-II proteins reduced the percentage of positive donors indicating that the T cell activation, observed as an increase in CD134 and/or CD137 expression, and determining positive donors is dependent on antigen presentation.
  • a method for determining the propensity of an antibody to elicit production of ADAs has been developed herein.
  • a potential challenge of a PBMCs-based assay is interference by the bioactivity of the biotherapeutic of interest, such as immune modulation through direct T cell engagement.
  • a second dendritic cell-T cell assay platform was developed.
  • PBMC are isolated from naive healthy donor’s blood by density gradient centrifugation using Uni-Sep blood separation tubes and are frozen (max 30xl0 6 PBMCs per tube) in at least 2 tubes.
  • Figure 9 and Figure 10 provide schematics of the experimental details of this method, where Figure 10 provides further details regarding the conditions.
  • CD14+ monocytes are isolated from at least 1 tube of PBMCs.
  • CD14+ monocytes are cultured at a density of l.OxlO 6 cells per ml in a 24-well plate with DC Media (RPMI, 1% Non-Essential amino acids, l% Na-Pyruvate, l% Kanamycin, 10% AB serum) supplemented with IL4 (17.2 ng/mL) and GM-CSF (66.6 ng/mL) for 24 hours, and placed in a 5% CO2 incubator.
  • DC Media RPMI, 1% Non-Essential amino acids, l% Na-Pyruvate, l% Kanamycin, 10% AB serum
  • IL4 17.2 ng/mL
  • GM-CSF 66.6 ng/mL
  • the monocyte-derived DCs were washed with sterile PBS and cultured with DC media containing IL4 (17.2 ng/mL), GM-CSF (66.6 ng/mL), TNF-a (5 ng/mL), IL-lp (5 ng/mL), IL-6 (150 ng/mL), PGE2 (1 pg/mL), and 100 pg/ml of the biotherapeutic tested.
  • Cells were placed in a 5% CO2 incubator.
  • the monocyte-derived DCs were then cultured at a concentration of 0.1 million/mL - 200 pL per well (20,000 cells/well in 96 well plate) to enable maturation of the DC for another 24 hours.
  • the mature DCs were exposed to the biotherapeutic for 24 hours to allow antigen uptake and processing and presentation of the antigenic peptides.
  • CD4+ cells from the same autologous PBMC population (from an earlier tube) were isolated.
  • the mature DCs were washed 3 times with PBS.
  • the CD4+ T cells and matured DCs were co-cultured at a ratio of 5 T cells to 1 DC (200,000 T cells + 20,000 DCs). This method allows precise control of the ratio of CD4+ T cells to APCs, which improves assay sensitivity.
  • the ratio of CD4+ T cells and DCs can vary (5: 1, 10: 1 and 20: 1) and can be further modified.
  • Cells were cultured for at least 19 hours in a 5% CO2 incubator (for a variable amount of time which could include 24 hours, 48 hours, or 72 hours). All samples were tested in triplicate. For each donor, responses to a negative control consisting of medium- treated cells (referred to as the unstimulated cells) were analyzed. CD4 activation was measured by the use of CD4, CD134, CD137 antibodies and live marker. The cells were analyzed by flow cytometry and plots are analyzed using FlowJo FACS analysis software (Tree Star, Inc.; Ashland, OR).
  • the stimulation index (SI) was calculated by dividing the mean and/or max percent of cells that are [live+CD4+CD134+CD137+, live+CD4+CD134+CD137- and live+CD4+CD134-CD137+] of each treatment by the mean and/or max percent of cells that are [live+CD4+CD134+CD137+ and live+CD4+CD134+CD137-and live+CD4+CD134-CD137+] of the medium-only treated well (unstimulated cells).
  • TDB1, TDB2, TDB3, TDB4 and TDB5 were analyzed by the method described above. As shown in Figures 11 A, 1 IB, 12A and 12B, the stimulation indexes of the bispecific antibodies were higher than that of AVASTIN®, which is known to have a low ADA rate. These data suggest that all five bispecific antibodies would be more immunogenic than AVASTIN®.
  • Fig. 14 provides an analysis of a bispecific antibody that has a binding specificity for T cells produced by two different methods. The first method includes the expression of both antigen-binding domains in a single cell to generate the bispecific antibody, which is recited as TDB4A in Fig. 14.
  • the second method includes the expression of each antigen-binding domain in a separate cell and the subsequent isolation and combination of the antigen-binding domains to generate the bispecific antibody, which is recited as TDB4B in Fig. 14. As shown in Fig. 14, TDB4B resulted in a higher stimulation index than TDB4A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention divulgue des procédés de détermination de la propension d'une composition, par exemple une composition comprenant un anticorps ou un de ses fragments, à déclencher une production d'anticorps anti-médicament (ADA), ainsi que des kits de mise en œuvre de ces procédés.
PCT/US2021/044704 2020-08-07 2021-08-05 Procédés faisant appel à des lymphocytes t pour prédire l'immunogénicité d'un polypeptide WO2022031948A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP21769836.4A EP4192942A1 (fr) 2020-08-07 2021-08-05 Procédés faisant appel à des lymphocytes t pour prédire l'immunogénicité d'un polypeptide
CN202180049073.8A CN115836122A (zh) 2020-08-07 2021-08-05 用于预测多肽免疫原性的基于t细胞的方法
JP2023504732A JP2023537683A (ja) 2020-08-07 2021-08-05 ポリペプチド免疫原性を予測するためのｔ細胞ベースの方法
US18/104,825 US20230184747A1 (en) 2020-08-07 2023-02-02 T cell-based methods for predicting polypeptide immunogenicity

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063062991P 2020-08-07 2020-08-07
US63/062,991 2020-08-07
US202163215199P 2021-06-25 2021-06-25
US63/215,199 2021-06-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/104,825 Continuation US20230184747A1 (en) 2020-08-07 2023-02-02 T cell-based methods for predicting polypeptide immunogenicity

Publications (1)

Publication Number Publication Date
WO2022031948A1 true WO2022031948A1 (fr) 2022-02-10

Family

ID=77739126

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/044704 WO2022031948A1 (fr) 2020-08-07 2021-08-05 Procédés faisant appel à des lymphocytes t pour prédire l'immunogénicité d'un polypeptide

Country Status (6)

Country Link
US (1) US20230184747A1 (fr)
EP (1) EP4192942A1 (fr)
JP (1) JP2023537683A (fr)
CN (1) CN115836122A (fr)
TW (1) TW202221116A (fr)
WO (1) WO2022031948A1 (fr)

Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0404097A2 (fr) 1989-06-22 1990-12-27 BEHRINGWERKE Aktiengesellschaft Récepteurs mono- et oligovalents, bispécifiques et oligospécifiques, ainsi que leur production et application
EP0425235A2 (fr) 1989-10-25 1991-05-02 Immunogen Inc Agents cytotoxiques contenant des maytansinoides et leur application thérapeutique
WO1993001161A1 (fr) 1991-07-11 1993-01-21 Pfizer Limited Procede de preparation d'intermediaires de sertraline
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
WO1993016185A2 (fr) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Proteine de liaison biosynthetique pour marqueur de cancer
WO1994011026A2 (fr) 1992-11-13 1994-05-26 Idec Pharmaceuticals Corporation Application therapeutique d'anticorps chimeriques et radio-marques contre l'antigene a differentiation restreinte des lymphocytes b humains pour le traitement du lymphome des cellules b
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5739116A (en) 1994-06-03 1998-04-14 American Cyanamid Company Enediyne derivatives useful for the synthesis of conjugates of methyltrithio antitumor agents
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5770710A (en) 1987-10-30 1998-06-23 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methlytrithio group
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6248516B1 (en) 1988-11-11 2001-06-19 Medical Research Council Single domain ligands, receptors comprising said ligands methods for their production, and use of said ligands and receptors
US6630579B2 (en) 1999-12-29 2003-10-07 Immunogen Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
US20060025576A1 (en) 2000-04-11 2006-02-02 Genentech, Inc. Multivalent antibodies and uses therefor
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
EP2101823B1 (fr) 2007-01-09 2016-11-23 CureVac AG Anticorps code par un arn
CN108578690A (zh) * 2018-05-16 2018-09-28 淮安诺康生物科技有限公司 一种tlr5激活剂用于激活抗原提呈细胞进而增强肿瘤细胞疫苗免疫原性的用途

Patent Citations (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5770710A (en) 1987-10-30 1998-06-23 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methlytrithio group
US6248516B1 (en) 1988-11-11 2001-06-19 Medical Research Council Single domain ligands, receptors comprising said ligands methods for their production, and use of said ligands and receptors
EP0404097A2 (fr) 1989-06-22 1990-12-27 BEHRINGWERKE Aktiengesellschaft Récepteurs mono- et oligovalents, bispécifiques et oligospécifiques, ainsi que leur production et application
US5416064A (en) 1989-10-25 1995-05-16 Immunogen, Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
EP0425235A2 (fr) 1989-10-25 1991-05-02 Immunogen Inc Agents cytotoxiques contenant des maytansinoides et leur application thérapeutique
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1993001161A1 (fr) 1991-07-11 1993-01-21 Pfizer Limited Procede de preparation d'intermediaires de sertraline
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993016185A2 (fr) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Proteine de liaison biosynthetique pour marqueur de cancer
WO1994011026A2 (fr) 1992-11-13 1994-05-26 Idec Pharmaceuticals Corporation Application therapeutique d'anticorps chimeriques et radio-marques contre l'antigene a differentiation restreinte des lymphocytes b humains pour le traitement du lymphome des cellules b
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5739116A (en) 1994-06-03 1998-04-14 American Cyanamid Company Enediyne derivatives useful for the synthesis of conjugates of methyltrithio antitumor agents
US5767285A (en) 1994-06-03 1998-06-16 American Cyanamid Company Linkers useful for the synthesis of conjugates of methyltrithio antitumor agents
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5877296A (en) 1994-06-03 1999-03-02 American Cyanamid Company Process for preparing conjugates of methyltrithio antitumor agents
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6630579B2 (en) 1999-12-29 2003-10-07 Immunogen Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
US20060025576A1 (en) 2000-04-11 2006-02-02 Genentech, Inc. Multivalent antibodies and uses therefor
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
EP2101823B1 (fr) 2007-01-09 2016-11-23 CureVac AG Anticorps code par un arn
CN108578690A (zh) * 2018-05-16 2018-09-28 淮安诺康生物科技有限公司 一种tlr5激活剂用于激活抗原提呈细胞进而增强肿瘤细胞疫苗免疫原性的用途

Non-Patent Citations (29)

* Cited by examiner, † Cited by third party
Title
CHARI ET AL., CANCER RES., vol. 52, 1992, pages 127 - 131
CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
CLARKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
DUBOWCHIK ET AL., BIOORG. & MED. CHEM. LETTERS, vol. 12, 2002, pages 1529 - 1532
FLATMAN ET AL., J. CHROMATOGR. B, vol. 848, 2007, pages 79 - 87
GARCIA-GARIJO ET AL., FRONT IMMUNOL, vol. 10, no. 1392, 2019
HALEMARHAM, THE HARPER COLLINS DICTIONARY OF BIOLOGY, 1991
HINMAN ET AL., CANCER RES., vol. 53, 1993, pages 3336 - 3342
HOLLINGER ET AL., PROC. NATL. ACAD. SCI., vol. 90, 1993, pages 6444 - 6448
HUDSON ET AL., NAT. MED., vol. 9, 2003, pages 129 - 134
IEZZI ET AL., FRONT IMMUNOL, vol. 9, no. 273, 2018
JEFFREY ET AL., BIOORGANIC & MED. CHEM. LETTERS, vol. 16, 2006, pages 358 - 362
JIANG ET AL., J. OF HEMATOLOGY & ONCOLOGY, vol. 12, no. 93, 2019
KATHLEEN PRATT: "Anti-Drug Antibodies: Emerging Approaches to Predict, Reduce or Reverse Biotherapeutic Immunogenicity", ANTIBODIES, vol. 7, no. 2, 31 May 2018 (2018-05-31), pages 19, XP055707955, DOI: 10.3390/antib7020019 *
KINDT ET AL.: "Kuby Immunology", 2007, W.H. FREEMAN AND CO., pages: 91
KING ET AL., J. MED. CHEM., vol. 45, 2002, pages 4336 - 4343
KRATZ ET AL., CURRENT MED. CHEM., vol. 13, 2006, pages 477 - 523
LODE ET AL., CANCER RES., vol. 58, 1998, pages 2925 - 2928
MACCALLUM ET AL., J. MOL. BIOL., vol. 262, 1996, pages 732 - 745
MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855
NAGY ET AL., PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 829 - 834
PLUCKTHUN: "The Pharmacology of Monoclonal Antibodies", vol. 113, 1994, SPRINGER-VERLAG, pages: 269 - 315
PORTOLANO ET AL., J. IMMUNOL., vol. 150, 1993, pages 880 - 887
PRABAKARAN ET AL., WIRES SYST BIOL MED, 2012
STADLER ET AL.: "Nature Medicine", 12 June 2017
SWAMINATHAN SETHU ET AL: "Immunogenicity to Biologics: Mechanisms, Prediction and Reduction", ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, BIRKHAEUSER-VERLAG, BASEL, CH, vol. 60, no. 5, 29 August 2012 (2012-08-29), pages 331 - 344, XP035110564, ISSN: 1661-4917, DOI: 10.1007/S00005-012-0189-7 *
TORGOV ET AL., BIOCONJ. CHEM., vol. 16, 2005, pages 717 - 721
VITETTA ET AL., SCIENCE, vol. 238, no. 1098, 1987
WEN YI ET AL: "Development of a FRET-Based Assay for Analysis of mAbs Internalization and Processing by Dendritic Cells in Preclinical Immunogenicity Risk Assessment", THE AAPS JOURNAL, SPRINGER INTERNATIONAL PUBLISHING, CHAM, vol. 22, no. 3, 16 April 2020 (2020-04-16), XP037153116, DOI: 10.1208/S12248-020-00444-1 *

Also Published As

Publication number Publication date
JP2023537683A (ja) 2023-09-05
US20230184747A1 (en) 2023-06-15
TW202221116A (zh) 2022-06-01
CN115836122A (zh) 2023-03-21
EP4192942A1 (fr) 2023-06-14

Similar Documents

Publication Publication Date Title
JP6517357B2 (ja) 抗ｔｉｍ３抗体及び使用方法
US20210025890A1 (en) Methods for detecting and quantifying fgf21
KR20210005080A (ko) 항-hla-g 항체 및 이의 용도
JP2018537951A (ja) 抗ｐｄ１抗体と使用方法
JP2017522903A (ja) Ｃｄ１２７に対する抗体
CN117777294A (zh) 抗hla-dq2.5抗体
US20230028050A1 (en) Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods
CN113329770A (zh) 新型癌抗原及所述抗原的抗体
JP2018535649A (ja) 抗ｏｘ４０抗体及びその診断用途
EP3533459A1 (fr) Anticorps anti-pla2-gib et leurs utilisations
US20230184747A1 (en) T cell-based methods for predicting polypeptide immunogenicity
US20230160907A1 (en) Cell-based methods for predicting polypeptide immunogenicity
US20240165252A1 (en) Antibody-drug conjugate and medical use thereof
WO2021010326A1 (fr) Anticorps de fgfr3 de type anti-mutation et son utilisation
US11845791B2 (en) Antibodies directed against GDF-15
TW202321299A (zh) 製造或使用ｉｌ—２３ｒ結合蛋白之材料及方法
EP4376887A2 (fr) Matériaux et procédés de fabrication ou d'utilisation de protéines de liaison à il-23 r
Jefferis et al. Structure and Function of Antibodies
CN116601173A (zh) 抗铜蓝蛋白抗体及其用途
WO2022029660A1 (fr) Anticorps anti-idiotypiques dirigés contre des domaines de liaison ciblés sur ror1 et compositions et procédés associés
IL311811A (en) Drug formulation of an anti-HLA-DQ2.5 antibody
WO2015164615A1 (fr) Anticorps anti-gluten et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21769836

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2023504732

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021769836

Country of ref document: EP

Effective date: 20230307